Needham Maintains Buy on AppLovin, Lowers Price Target to $475
Needham analyst Bernie McTernan maintains AppLovin (NASDAQ:APP) with a Buy and lowers the price target from $500 to $475.
Read original at benzingaStocks · News reference
Eli Lilly Could Swing Over $76 Billion In Value After Earnings
Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings reports.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 12:34 PM
- Checked
- Aug 3, 2026, 12:34 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
'DOJ, TikTok settle for $400 million in children's privacy suit' - Axios
https://www.axios.com/2026/08/21/doj-tiktok-biden-lawsuit-settlement
Read original at benzingaPiper Sandler Maintains Neutral on AppLovin, Lowers Price Target to $325
Piper Sandler analyst James Callahan maintains AppLovin (NASDAQ:APP) with a Neutral and lowers the price target from $385 to $325.
Read original at benzingaAppLovin vs. CoreWeave: What Recent Revenue Trends Tell Investors
CoreWeave has surpassed AppLovin in quarterly revenue, driven by strong AI infrastructure demand, with Q2 2026 revenue reaching $2.6 billion versus AppLovin's $1.9 billion. However, AppLovin maintains superior profitability with a 66% net income margin compared to CoreWeave's -24% margin. AppLovin's growth is decelerating, with Q2 year-over-year growth at 53% down from Q1's 59%, prompting analyst downgrades and a 52-week stock low.
Read original at the-motley-foolGilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer
Read original at benzingaInvesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?
The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.
Read original at the-motley-fool